Drugs

, Volume 63, Issue 17, pp 1813–1820 | Cite as

Treatment of Allergic Rhinitis During Pregnancy

  • Pascal Demoly
  • Vincent Piette
  • Jean-Pierre Daures
Review Article

Abstract

Allergic rhinitis is a frequent problem during pregnancy. In addition, physiological changes associated with pregnancy can affect the upper airways. Evidence-based guidelines on the management of allergic rhinitis have recently been published, the most recent being the Allergic Rhinitis and its Impact on Asthma (ARIA) — World Health Organization consensus. Many pregnant women experience allergic rhinitis and particular attention is required when prescribing drugs to these patients. Medication can be prescribed during pregnancy when the apparent benefit of the drug is greater than the apparent risk. Usually, there is at least one drug from each major class that can be safely utilised to control symptoms.

All glucocorticosteroids are teratogenic in animals but, when the indication is clear (for diseases possibly associated, such as severe asthma exacerbation), the benefit of the drug is far greater than the risk. Inhaled glucocorticosteroids (e.g. beclomethasone or budesonide) have not been incriminated as teratogens in humans and are used by pregnant women who have asthma. A few histamine H1-receptor antagonists (H1-antihistamines) can safely be used as well. Most oral decongestants (except pseudoephedrine) are teratogenic in animals. There are no such data available for intra-nasal decongestants. Finally, pregnancy is not considered as a contraindication for the continuation of allergen specific immunotherapy.

References

  1. 1.
    Ellegard E, Karlsson G. Nasal congestion during pregnancy. Clin Otolaryngol 1999; 24: 307–11PubMedCrossRefGoogle Scholar
  2. 2.
    Ellegard E, Karlsson G. IgE-mediated reactions and hyperreactivity in pregnancy rhinitis. Arch Otolaryngol Head Neck Surg 1999; 125: 1121–5PubMedGoogle Scholar
  3. 3.
    Sorri M, Hartikainen-Sorri AL, Karja J. Rhinitis during pregnancy. Rhinology 1980; 18: 83–6PubMedGoogle Scholar
  4. 4.
    The use of newer asthma and allergy medications during pregnancy. The American College of Obstetricians and Gynecologists (ACOG) and The American College of Allergy, Asthma and Immunology (ACAAI). Ann Allergy Asthma Immunol 2000; 84: 475–80CrossRefGoogle Scholar
  5. 5.
    Schatz M. Special considerations for the pregnant woman and senior citizen with airway disease. J Allergy Clin Immunol 1998; 101: S373–8PubMedCrossRefGoogle Scholar
  6. 6.
    Mazzotta P, Loebstein R, Koren G. Treating allergic rhinitis in pregnancy: safety considerations. Drug Saf 1999; 20: 361–75PubMedCrossRefGoogle Scholar
  7. 7.
    Bousquet J, van-Cauwenberge P, Khaltaev N, et al. Allergic rhinitis and its impact on asthma (ARIA): in collaboration with the World Health Organization. J Allergy Clin Immunol 2001; 108: S1–S315CrossRefGoogle Scholar
  8. 8.
    Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ 1998; 317: 1624–9PubMedCrossRefGoogle Scholar
  9. 9.
    Ellegard EK, Hellgren M, Karlsson NG. Fluticasone propionate aqueous nasal spray in pregnancy rhinitis. Clin Otolaryngol 2001; 26: 394–400PubMedCrossRefGoogle Scholar
  10. 10.
    Cave A, Arlett P, Lee E. Inhaled and nasal corticosteroids: factors affecting the risks of systemic adverse effects. Pharmacol Ther 1999; 83: 153–79PubMedCrossRefGoogle Scholar
  11. 11.
    Kusanagi T. Occurrence of cleft palate, palatal slit, and fetal death in mice treated with a glucocorticoid: an embryo transfer experiment. Teratology 1983; 27: 395–400PubMedCrossRefGoogle Scholar
  12. 12.
    Greenberger PA, Patterson R. Beclomethasone diproprionate for severe asthma during pregnancy. Ann Intern Med 1983; 98: 478–80PubMedGoogle Scholar
  13. 13.
    Briggs GC, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 8th ed. Baltimore (MD): Lippincott Williams & Wilkins, 1998Google Scholar
  14. 14.
    Kallen B, Rydhstroem H, Aberg A. Congenital malformations after the use of inhaled budesonide in early pregnancy. Obstet Gynecol 1999; 93: 392–5PubMedCrossRefGoogle Scholar
  15. 15.
    Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000; 62: 385–92PubMedCrossRefGoogle Scholar
  16. 16.
    Reinisch JM, Simon NG, Karow WG, et al. Prenatal exposure to prednisone in humans and animals retards intrauterine growth. Science 1978; 202: 436–8PubMedCrossRefGoogle Scholar
  17. 17.
    Schatz M, Zeiger RS, Harden K, et al. The safety of asthma and allergy medications during pregnancy. J Allergy Clin Immunol 1997; 100: 301–6PubMedCrossRefGoogle Scholar
  18. 18.
    Schatz M, Patterson R, Zeitz S, et al. Corticosteroid therapy for the pregnant asthmatic patient. JAMA 1975; 233: 804–7PubMedCrossRefGoogle Scholar
  19. 19.
    Snyder RD, Snyder D. Corticosteroids for asthma during pregnancy. Ann Allergy 1978; 41: 340–1PubMedGoogle Scholar
  20. 20.
    Orr TS. Mode of action of disodium cromoglycate. Acta Allergol 1977; 13: 9–27PubMedGoogle Scholar
  21. 21.
    Norris AA. Pharmacology of sodium cromoglycate. Clin Exp Allergy 1996; 4: 5–7CrossRefGoogle Scholar
  22. 22.
    Wilson J. Use of sodium cromoglycate during pregnancy. Acta Ther 1982; 8: S45–51Google Scholar
  23. 23.
    Gengo FM, Manning C. A review of the effects of antihistamines on mental processes related to automobile driving. J Allergy Clin Immunol 1990; 86: 1034–9PubMedCrossRefGoogle Scholar
  24. 24.
    Walker BE, Patterson A. Induction of cleft palate in mice by tranquilizers and barbiturates. Teratology 1974; 10: 159–63PubMedCrossRefGoogle Scholar
  25. 25.
    King CT, Howell J. Teratogenic effect of buclizine and hydroxyzine in the rat and chlorcyclizine in the mouse. Am J Obstet Gynecol 1966; 95: 109–11PubMedGoogle Scholar
  26. 26.
    Saxen I. Cleft palate and maternal diphenhydramine intake. Lancet 1974; I: 407–8CrossRefGoogle Scholar
  27. 27.
    Schatz M, Petitti D. Antihistamines and pregnancy. Ann Allergy Asthma Immunol 1997; 78: 157–9PubMedCrossRefGoogle Scholar
  28. 28.
    Ciprandi G, Liccardi G, D’Amato G, et al. Treatment of allergic diseases during pregnancy. J Investig Allergol Clin Immunol 1997; 7: 557–65PubMedGoogle Scholar
  29. 29.
    Einarson A, Bailey B, Jung G, et al. Prospective controlled study of hydroxyzine and cetirizine in pregnancy. Ann Allergy Asthma Immunol 1997; 78: 183–6PubMedCrossRefGoogle Scholar
  30. 30.
    Källen B. Drugs in pregnancy: the dilemma of labeling. Drug Inf J 1999; 33: 1135–43CrossRefGoogle Scholar
  31. 31.
    Kallen B. Use of antihistamine drugs in early pregnancy and delivery outcome. J Matern Fetal Neonatal Med 2002; 11(3): 146–52PubMedCrossRefGoogle Scholar
  32. 32.
    The European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products Meeting of 17 to 18 December 2002 [media release]. London: The European Agency for the Evaluation of Medicinal Products, 2002 Dec 19Google Scholar
  33. 33.
    Moretti ME, Caprara D, Coutinho CJ, et al. Fetal safety of loratadine use in the first trimester of pregnancy: a multicenter study. J Allergy Clin Immunol 2003; 111(3): 479–83PubMedCrossRefGoogle Scholar
  34. 34.
    Wood CC, Fireman P, Grossman J, et al. Product characteristics and pharmacokinetics of intranasal ipratropium bromide. J Allergy Clin Immunol 1995; 95: 1111–6PubMedCrossRefGoogle Scholar
  35. 35.
    Malm L. Pharmacological background to decongesting and antiinflammatory treatment of rhinitis and sinusitis. Acta Otolaryngol Suppl 1994; 515: 53–5PubMedCrossRefGoogle Scholar
  36. 36.
    Johnson DA, Hricik JG. The pharmacology of alpha-adrenergic decongestants. Pharmacotherapy 1993; 13: 110S–5SPubMedGoogle Scholar
  37. 37.
    Graf P, Hallen H, Juto JE. Four-week use of oxymetazoline nasal spray (Nezeril) once daily at night induces rebound swelling and nasal hyperreactivity. Acta Otolaryngol 1995; 115: 71–5PubMedCrossRefGoogle Scholar
  38. 38.
    Kanfer I, Dowse R, Vuma V. Pharmacokinetics of oral decongestants. Pharmacotherapy 1993; 13: 116S–28SPubMedGoogle Scholar
  39. 39.
    Werler MM, Mitchell AA, Shapiro S. First trimester maternal medication use in relation to gastroschisis. Teratology 1992; 45: 361–7PubMedCrossRefGoogle Scholar
  40. 40.
    Aselton P, Jick H, Milunsky A, et al. First-trimester drug use and congenital disorders. Obstet Gynecol 1985; 65: 451–5PubMedGoogle Scholar
  41. 41.
    Jick H, Holmes LB, Hunter JR, et al. First-trimester drug use and congenital disorders. JAMA 1981; 246: 343–6PubMedCrossRefGoogle Scholar
  42. 42.
    Bousquet J, Lockey R, Mailing HJ, et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases: a WHO position paper. J Allergy Clin Immunol 1998; 102: 558–62PubMedCrossRefGoogle Scholar
  43. 43.
    Metzger WJ, Turner E, Patterson R. The safety of immunotherapy during pregnancy. J Allergy Clin Immunol 1978; 61: 268–72PubMedCrossRefGoogle Scholar
  44. 44.
    Nuutinen J, Holopainen E, Haahtela T, et al. Balanced physiological saline in the treatment of chronic rhinitis. Rhinology 1986; 24: 265–9PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  • Pascal Demoly
    • 1
  • Vincent Piette
    • 1
  • Jean-Pierre Daures
    • 2
  1. 1.Department of Respiratory Medicine, Hospital Arnaud de VilleneuveUniversity Hospital of MontpellierMontpellierFrance
  2. 2.Montpellier University Clinical Research InstituteMontpellierFrance

Personalised recommendations